ACADIA PHARMACEUTICALS INC
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.
On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.
The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.
Extracted from this filing and checked against the source text.
Elena Ridloff resigned as Executive Vice President and Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.View on SEC.gov
Stephen Davis was appointed as principal financial officer at ACADIA PHARMACEUTICALS INC.
On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.View on SEC.gov
Mark Schneyer was appointed as interim Chief Financial Officer at ACADIA PHARMACEUTICALS INC.
The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.